People that have more distant tumors — tumors that have spread to distant parts away from the primary site — have higher mortality rate when compared to people with only localized tumors. Age of Diagnosis
In a 2020 case study of 464 adolescents aged 0–19 years diagnosed with rhabdomyosarcoma between 1988 to 2016, children who were diagnosed between ages 5–9 years had the most promising prognosis. In contrast, infants less than 1 years old had the worst outcome, which may be associated to the lower doses of chemotherapy and radiotherapy administered and naive immune system. Treatment
Treatment for embryonal rhabdomyosarcoma involves the use of combination therapy consisting of chemotherapy, surgery, and/or radiation therapy. In order to create an optimal treatment plan for the individual, therapy is often based upon risk stratigication (low, intermediate, or high risk) based off of individuals disease stage, size of tumor, progression of disease, surgery resection, age at diagnosis, and site of tumor. In the US, a combination of Vincristine, Actinomycin D, and cyclophosphamide are often the chemotherapeutics used to treat rhabdomyosarcoma. In contrast, the regimen in Europe utilizes Vincristine, Actinomycin D, and ifosfamide. When the US and European regimen were studied side by side, the two regimens were comparable in terms of efficacy outcomes. Radiation therapy continues to be an integral component of rhabdomyosarcoma treatment, however, the long-term safety and treatment related complications remain a concern.
Of these, RIC has the most robust clinical evidence, especially in the context of STEMI, but also emerging for other indications such as acute ischemic stroke and aneurysmal subarachnoid hemorrhage. Neonatal thrombosis
Treatment options for full-term and preterm babies who develop thromboembolism include expectant management (with careful observation), nitroglycerin ointment, pharmacological therapy (thrombolytics and/or anticoagulants), and surgery. The evidence supporting these treatment approaches is weak. For anticoagulant treatment, t is not clear if unfractionated and/or low molecular weight heparin treatment is effective at decreasing mortality and serious adverse events in this population. There is also insufficient evidence to understand the risk of adverse effects associated with these treatment approaches in term or preterm infants. See also
Blood clotting tests
Disseminated intravascular coagulation
Hepatic artery thrombosis
Thrombotic microangiopathy

References
Bibliography
Brunner, Lillian (2010). Brunner & Suddarths textbook of medical-surgical nursing. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 978-0781785907. Copstead, Lee (2013). Pathophysiology. St. Louis, Mo: Elsevier. ISBN 978-1455726509. Hoffman, Barbara (2012). Williams gynecology. New York: McGraw-Hill Medical. ISBN 978-0071716727. Moliterno, David (2013). Therapeutic advances in thrombosis. Chichester, West Sussex: Wiley-Blackwell. ISBN 978-1405196253. Abele, H (2014). Atlas of gynecologic surgery. Stuttgart: Thieme. ISBN 978-3136507049; Access provided by the University of Pittsburgh{{cite book}}:  CS1 maint: postscript (link)

External links
 Media related to Thrombosis at Wikimedia Commons
Thrombosis at Curlie